About kazia therapeutics - KZIA
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
KZIA At a Glance
Kazia Therapeutics Ltd.
Three International Towers
Sydney, New South Wales (NSW) 2000
| Phone | 61-2-9472-4101 | Revenue | 27.20K | |
| Industry | Biotechnology | Net Income | -13,407,256.74 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
KZIA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 252.612 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.439 |
| Enterprise Value to Sales | 157.468 |
| Total Debt to Enterprise Value | 0.061 |
KZIA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 0.424 |
| Total Asset Turnover | 0.003 |
KZIA Liquidity
| Current Ratio | 0.351 |
| Quick Ratio | 0.351 |
| Cash Ratio | 0.309 |
KZIA Profitability
| Gross Margin | -2,123.81 |
| Operating Margin | -38,104.775 |
| Pretax Margin | -53,945.238 |
| Net Margin | -49,290.476 |
| Return on Assets | -145.829 |
| Return on Equity | N/A |
| Return on Total Capital | 258.80 |
| Return on Invested Capital | N/A |
KZIA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -5.009 |
| Total Debt to Total Assets | 6.534 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |